A comparison of the efficacy of latanoprost, travoprost and bimatoprost in open angle glaucoma and ocular hypertension

Yıl 2012, Cilt: 29 Sayı: 2s, 89 - 92, 22.06.2012

Özlem Eşki Yücel , Nurşen Arıtürk

https://doi.org/10.5835/jecm.omu.29.s2.008

Öz

he aim of this study was to compare the efficacy and safety of latanoprost, travoprost and bimatoprost monotherapies in previously untreated patients with open angle glaucoma and ocular hypertension. This study included thirty-six eyes of 18 patients diagnosed with primary open angle glaucoma (POAG) and ocular hypertension (OHT) at Ondokuz Mayıs University, Medical Faculty, Department of Ophthalmology. All patients were underwent complete ophthalmic examination. Patients were randomized into 3 groups with six patients; group 1 received latanoprost 0.005% (Xalatan, Pharmacia), group 2 received travoprost 0.004% (Travatan, Alcon) and group 3 received bimatoprost 0.03% (Lumigan, Allergan) monotherapies. First examination was performed at the beginning of the study. Control examinations were performed at the 2, 4, 12 and 24th weeks of the therapy. Efficacy and side effects of these drugs were evaluated on each control visits. There were no significant differences in demographic characteristics among treatment groups. Baseline mean intra ocular pressure (IOP) levels were 26.50±3.14 mmHg in group 1, 25.58±3.62 mmHg in group 2 and 24.66±3.62 mmHg in group 3. Mean IOP levels were similar at end of the study between groups and 14.83±2.24 mmHg in group 1, 16.41±4.16 mmHg in group 2 and 16.16±3.53 mmHg in group 3. The most frequent side-effect was conjunctival hyperemia, which was determined in none of the patients in group 1, in 2 eyes in group 2 (16.7%) and 6 eyes in group 3 (50%). There was no statistically significant difference of IOP between latanoprost, travoprost and bimatoprost monotherapies. The side-effects were fewest in the latanoprost group and the most frequent in the bimatoprost group. 

Anahtar Kelimeler

Primary open angle glaucoma, Ocular hypertension, Latanoprost, Travoprost, Bimatoprost

Kaynakça

• AGIS Investigators, 2000.The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 130, 490-491.
• Alexander, C.L., Miller, S.J., Abel, S.R., 2002. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann. Pharmacother. 36, 504-511.
• Denis, P., Lafuma, A., Khoshnood, B., Mimaud, V., Berdeaux, G., 2007. A meta-analysis of topical prostoglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr. Med. Res. Opin. 23, 601-608.
• DuBiner, H., Cooke, D., Dirks, M., Stewart, W.C., VanDenburgh, A.M., Felix, C., 2001. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: A 30-day comparison with latanoprost. Surv. Ophthalmol. 45, 353-360.
• Guenoun, J.M., Baudouin, C., Rat, P., Pauly, A., Warnet, J.M., Brignole-Baudouin, F., 2005. ın vitro study of potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest. Ophthalmol. Vis. Sci. 46, 2444-2450.
• Hylton, C., Robin, A.L., 2003. Update on prostaglandin analogs. Curr. Opin. Ophthalmol. 14, 65-69.
• Netland, P.A., Landry, T., Sullivan, E.K., Andrew, R., Silver, L., Weiner, A.K., Mallick, S., Dickerson, J., Bergamini, M.V.W., Robertson, S.M., Davis, A.A., 2001. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma and ocular hypertension. Am. J. Ophthalmol. 132, 472-484.
• Noecker, R.S., Dirks, M.S., Choplin, N.T., Bernstein, P., Batoosingh, A.L., Whitcup, S.M., 2003. The Bimatoprost/Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am. J. Opthalmol. 135, 55-63.
• Ozdemir, N., Ozcan, A.A., Bilgiç, E., 2004. Bimatoprost, latanoprost ve travoprostun primer açık açılı glokom olgularında erken dönem yan etkileri ve göz içi basıncı üzerine etkinliği. T. Oft. Gaz. 33, 376-379.
• Parrish, R.K., Palmberg, P., Sheu, W.P., 2003. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12 week randomized, masked-evaluator multicenter study. Am. J. Ophthalmol. 135, 688-703.
• Perry, C.M., McGavin, J.K., Culy, C.R., Ibbotson, T., 2003. Latanoprost an update of its use in glaucoma and ocular hypertension. Drugs Aging. 20, 597-630.
• Sarıcaoğlu, M.S., Karakurt, A., Sengün, A., Hasıripi, H., Karabulut, E., 2005. Primer açık açılı glokom olgularında latanoprost, travoprost ve bimatoprostun yan etki profillerinin karşılaştırılması. M.N. Oftalmoloji. 12, 113-117.
• Sen, E.M., Tuna, T., Ural, F., Köklü, G., Fırat, E., 2006. Primer açık açılı glokom hastalarının tedavisinde latanoprost, travoprost ve bimatoprostun karşılaştırılması. T. Klin. J. Ophthalmol. 15, 12-17.
• Sherwood, M., Brandt, J., 2001. For the Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv. Ophthalmol. 45, 361-368.
• Smith, M.F., Doyle, J.W., 2004. Clinical examination of glaucoma. In Ophthalmology. Yanoff M., Duker J.S., eds. 11830 Westline Industrial Drive, St. Louis. 1431-1440
• Stewart, W.C., Kolker, A.E., Stewart, J.A., Leech, J., Jackson, A.L., 2003. Conjunctival hyperemia in healty subjects after short-term dosing with of latanoprost, bimatoprost, and travoprost. Am. J. Ophthalmol. 135, 314-320.
• Stjernschantz, J.W., Albert, D.M., Hu, D.N., Drago, F., Wistrand, P.J., 2002. Mechanism and clinical significance of prostoglandin induced iris pigmentation. Surv. Ophthalmol. 47, 162-175.
• Turaçlı, M.E., 2003. Tıbbi tedavi. In Glokom. Turaçlı M.E., Onol M., Yalvaç I.S., eds. SFN Televizyon Tanıtım Tasarım Yayıncılık, Ankara, pp. 163-195.
• Watson P., Stjernschantz, J., 1996. For the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 103, 126-137.
• Whitson, J.T., Trattler, W.B., Matossian, C., Williams, J., Hollander, D.A., 2010. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension. J. Ocul. Pharmacol. Ther. 26, 287-292.